News & Events

Press Releases

  • October 2025

    Draig Therapeutics Announces US FDA Clearance of IND Application for Phase 2 Study of DT-101 for the Treatment of Major Depressive Disorder

  • July 2025

    Draig Therapeutics Appoints Experienced Biotech Leader Douglas E. Williams, Ph.D. as Chair of its Board of Directors

  • June 2025

    Draig Therapeutics Launches with $140 Million to Advance Next-Generation Therapies for Major Neuropsychiatric Disorders